Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001437749-24-038128
Filing Date
2024-12-20
Accepted
2024-12-20 16:30:22
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 7058
  Complete submission text file 0001437749-24-038128.txt   8657
Mailing Address 10080 N WOLFE ROAD SUITE SW3-200 CUPERTINO CA 95014
Business Address 10080 N WOLFE ROAD SUITE SW3-200 CUPERTINO CA 95014 4085018881
REVIVA PHARMACEUTICALS HOLDINGS, INC. (Subject) CIK: 0001742927 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-90624 | Film No.: 241568389
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 19925 STEVENS CREEK BLVD., SUITE 100 CUPERTINO CA 95014
Business Address
Bhat Laxminarayan (Filed by) CIK: 0001818245 (see all company filings)

Type: SCHEDULE 13D/A